A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction

被引：2
|
作者：
Saunders, Ila Maewal [1 ]
Gulbis, Alison [1 ]
Champlin, Richard E. [2 ]
Qazilbash, Muzaffar H. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2014年 / 20卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2013.12.496
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
459
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [21] Comparison of 140mg/m2 vs 200mg/m2 Dose of Melphalan in Myeloma Autograft - a Single Centre Experience from Chennai, India
    Kumar, Kishore
    Subash, Chezhian
    BLOOD, 2020, 136
  • [22] PHARMACOKINETICS PARAMETERS AND TOXICITY OF HIGH-DOSE 140 MG/M2 MELPHALAN - FEASIBILITY IN PATIENTS WITH SEVERE RENAL-FAILURE
    MOREAU, P
    KERGUERIS, MF
    MILPIED, N
    LEGROS, L
    LAROUSSE, C
    HAROUSSEAU, JL
    BLOOD, 1994, 84 (10) : A657 - A657
  • [23] Prospective, randomized comparison between double mransplantation (T) with melphalan (200 mg/m2) and triple T with intermediate dose melphalan (100 mg/m2) in patients with multiple myeloma (an interim analysis).
    Ludwig, Heinz
    Linkesch, Werner
    Kasparu, Hedwig
    Krieger, Otto
    Spicka, Ivan
    Gastl, Gunther
    Greil, Richard
    Drach, Johannes
    Thaler, Josef
    Kuhn, Ingrid
    Zojer, Niklas
    Hinke, Axel
    BLOOD, 2006, 108 (11) : 878A - 879A
  • [24] Evaluation of different intermediate melphalan doses (80 mg/m2 vs 100 mg/m2 vs 120 mg/m2) in multiple myeloma patients.
    Palumbo, A
    Triolo, S
    Argentino, C
    Bringhen, S
    Dominietto, A
    Giaccone, L
    Rus, C
    Omedè, P
    Pileri, A
    Boccadoro, M
    BLOOD, 1999, 94 (10) : 578A - 578A
  • [25] In myeloma patients treated with melphalan 100mg/m2 or melphalan 200mg/m2 outcome is not significantly different.
    Palumbo, A
    Triolo, S
    Bringhen, S
    Rus, C
    Omedè, P
    Bertola, A
    Giaccone, L
    Bianchi, A
    Bruno, B
    Tarella, C
    Caravita, T
    Musto, P
    Amadori, S
    Carotenuto, M
    Pileri, A
    Boccadoro, M
    BLOOD, 2000, 96 (11) : 419A - 419A
  • [26] Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
    Jose Lahuerta, Juan
    Victoria Mateos, Maria
    Martinez-Lopez, Joaquin
    Grande, Carlos
    de la Rubia, Javier
    Rosinol, Laura
    Sureda, Anna
    Garcia-Larana, Jose
    Diaz-Mediavilla, Joaquin
    Hernandez-Garcia, Miguel T.
    Carrera, Dolores
    Besalduch, Joan
    de Arriba, Felipe
    Oriol, Albert
    Escoda, Lourdes
    Garcia-Frade, Javier
    Rivas-Gonzalez, Concepcion
    Alegre, Adrian
    Blade, Joan
    San Miguel, Jesus F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1913 - 1920
  • [27] Melphalan 200 mg/m2 versus 100 mg/m2 in newly diagnosed myeloma
    Palumbo, A.
    Bringhen, S.
    Petrucci, M. T.
    Falcone, A.
    Liberati, A. M.
    Lauta, V. M.
    Montanaro, M.
    Cangialosi, C.
    Morandi, S.
    D'Agostino, F.
    Cavallo, F.
    Omede, P.
    Musto, P.
    Foue, R.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 189 - 189
  • [28] Salvage treatment with melphalan 100 mg/m2 in fulminant progression of multiple myeloma
    Hajek, R.
    Krejci, M.
    Krivanova, A.
    Pour, L.
    Adam, Z.
    Zahradova, L.
    Vetesnikova, E.
    Mayer, J.
    Vorlicek, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 95 - 96
  • [29] Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma.: Preliminary results of the IFM 9502 randomized trial.
    Harousseau, JLM
    Facon, T
    Moreau, P
    Michallet, M
    Guilhot, F
    Hulin, C
    Doyen, C
    François, S
    Marit, G
    Maloisel, F
    Attal, M
    BLOOD, 1999, 94 (10) : 713A - 713A
  • [30] INTERMEDIATE-DOSE (25 MG/M2) INTRAVENOUS MELPHALAN FOR PATIENTS WITH MULTIPLE-MYELOMA IN RELAPSE OR REFRACTORY TO STANDARD TREATMENT
    PETRUCCI, MT
    AVVISATI, G
    TRIBALTO, M
    CANTONETTI, M
    GIOVANGROSSI, P
    MANDELLI, F
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 42 (03) : 233 - 237
12345